New Study Boosts Genetic Testing Accessibility for Breast Cancer in the Netherlands
Utrecht, Monday, 14 July 2025.
In the Netherlands, a mainstream genetic testing pathway has significantly increased testing uptake among breast cancer patients, promoting equity across socio-economic groups, as revealed by a recent study.
Improving Accessibility Through Mainstream Genetic Testing
A recent nationwide study conducted by the Netherlands Comprehensive Cancer Organisation (IKNL) underscores the transformative impact of a mainstream genetic testing pathway for breast cancer patients in the Netherlands. The study demonstrates that this strategy significantly bolstered the uptake of genetic testing among eligible patients, with a remarkable increase from 63% for those referred to conventional genetics departments to 78% under the new pathway [1]. The mainstream genetic testing (MGT) approach, facilitated by non-genetic healthcare professionals, thus emerges as a boon for encouraging broader participation across varying socioeconomic statuses, promoting equity in healthcare access [1].
Healthcare Equity: A Step Forward
The initiative is notably significant in its potential to bridge gaps in access, as evidenced by the study’s findings that revealed disparities based on socioeconomic status. Previously, patients from lower socioeconomic backgrounds had significantly lower odds (OR 0.71) of accessing genetic testing when compared to their higher-status counterparts. However, the implementation of MGT effectively nullifies this gap, with no significant difference in testing uptake found between low and high SES groups (OR 0.75) [1]. This highlights the effectiveness of integrating MGT into routine healthcare practices, enhancing equity in cancer treatment initiation [1].
Implications for Healthcare Providers
The study advocates for extensive educational outreach to healthcare providers, urging them to embrace mainstream genetic testing. This is vital given that the involvement of non-genetic healthcare professionals in the pre-test phase is crucial for the pathway’s success [1]. Moreover, the study emphasizes that universal education on the existing disparities in genetic testing is essential, offering a compelling case for further integration of MGT into the Dutch healthcare framework. The research led by experts from the Netherlands Comprehensive Cancer Organisation and several Dutch academic institutions [1] serves as a cornerstone for future policy-making aimed at improving health equity.
Driving Future Innovations
As healthcare systems worldwide strive for more inclusive approaches, the Dutch example provides a scalable model for other nations grappling with similar disparities in genetic testing. The broader integration of MGT could dramatically influence cancer prognosis and outcomes by ensuring timely detection and the right therapeutic pathways [1]. This innovation is set against the backdrop of ongoing research efforts across Europe, where differences in healthcare access continue to challenge systemic equity [1].